Sort
82,697 grants matching “vaccine development”
HIV, TB, and Malaria Vaccine Development for Africa
$3,297,293Barton F Haynes · Duke University · P01 · FY2006 · AI
PHRU-Setshaba Clinical Trials Unit
$3,297,099Glenda E Gray · Wits Health Consortium (Pty), Ltd · UM1 · FY2022 · AI
Novel Adenovirus Vector-Based Vaccines for HIV-1
$3,296,945Beth Israel Deaconess Medical Center · U19 · FY2005 · AI
Operations and Management support component
$3,296,764Barton F Haynes · Duke University · UM1 · FY2017 · AI
Brief digital intervention to increase COVID-19 vaccination among individuals with anxiety or depression
$3,296,734Denis Nash · Graduate School Of Public Health And Health Policy · RF1 · FY2022 · MH
TCR Gene Modified T Cells for Adoptive Immunotherapy
$3,295,681Michael I Nishimura · Loyola University Chicago · P01 · FY2014 · CA
Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory
$3,293,351Erin June Adams · University Of Chicago · G20 · FY2022 · AI
Virus-Host Interactions: Induction and Evasion of Host Innate Immunity
$3,291,142Sonja Best · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
HIV Vaccine Trials Network Laboratory Center - B-Cell and Molecular Assay Multi-year Supplement
$3,287,548Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2024 · AI
Center for AIDS Research at Emory University
$3,287,506Carlos Del Rio · Emory University · P30 · FY2017 · AI
Columbia Collaborative HIV/AIDS Clinical Trials Unit
$3,286,124Scott M Hammer · Columbia University Health Sciences · U01 · FY2007 · AI
HIV, TB, and Malaria Vaccine Development for Africa
$3,284,182Barton F Haynes · Duke University · P01 · FY2007 · AI
Simian Vaccine Evaluation Unit (SVEU)
$3,283,375Michael Agy · University Of Washington · N01 · FY2012 · AI
Flow Cytometry Core
$3,281,700Steve Perfetto · National Institute Of Allergy And Infectious Diseases · ZIC · FY2022 · AI
Clarifying the interplay between herpesvirus infection and reactivation, immune responses, APOE genotype, and development of tau-pathology
$3,280,861Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health · RF1 · FY2025 · AG
NIAID VIROLOGY QUALITY ASSURANCE
$3,278,581James Bremer · Rush University Medical Center · N01 · FY2017 · AI
Conversational Agent to Improve Guideline Concordant Care for People with Cervical Cancer Screening Abnormalities
$3,277,279Rebecca Bernstein Perkins · Tufts Medical Center · R01 · FY2025 · CA
Systematic Development of Antiretroviral Intravaginal Rings for HIV Prevention
$3,274,930Marc Michael Baum · Oak Crest Institute Of Science · U19 · FY2014 · AI
Integrated Support Services-Animal
$3,274,714John R. Murphy · Boston University Medical Campus · UC7 · FY2014 · AI
Ebola Vaccine Development
$3,274,022Nancy J Sullivan · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Graft-versus-leukemia
$3,273,957Austin J Barrett · National Heart, Lung, And Blood Institute · ZIA · FY2010 · HL
HIV Prevention Trials Network: Network Laboratory
$3,273,493Susan H Eshleman · Johns Hopkins University · U01 · FY2008 · AI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines
$3,273,346University Of Alabama At Birmingham · U19 · FY2004 · AI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
$3,271,928Fred R Hirsch · Icahn School Of Medicine At Mount Sinai · U54 · FY2023 · CA
Vaccination and infection: indicators of immunological health and responsiveness
$3,271,801Mark M Davis · Stanford University · U19 · FY2011 · AI